FMS-like tyrosine kinase 3 (FLT3) mutations are common in patients with acute myeloid leukemia (AML), and is often associated with a poor prognosis. Despite the development of FLT3 inhibitors such as midostaurin, sorafenib, and qauizartinib, patients often progress on these therapies due to secondary mutations. Various strategies to improve patient outcomes such novel combinations with other agents including hypomethylating agents or venetoclax are currently under investigation.
In this podcast, Naval Daver, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, have an insightful discussion on FLT3-mutated acute myeloid leukemia (AML) updates presented at the ASH 2021 annual meeting. They give an overview of the use of FLT3 inhibitors in combination with other agents, as well as trial data from the LACEWING trial (NCT02752035) of gilteritinib in combination with azacitidine in the frontline setting.
This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
The CLL Sessions: highlights from ASH 2020
The Lymphoma Sessions: highlights from ASH 2020
The MDS Sessions: Giants in MDS
Latest therapies in AML: IMGN632, magrolimab & gilteritinib
VJSession: EBMT/EHA CAR-T Nursing Session
The Myeloma Sessions: key updates from ASH 2020
The MPN Sessions: Rapidly advancing genomic discoveries and treatment strategies in MPNs
Updates for the management of MDS from ASH 2020
The AML Sessions: highlights from ASH 2020
The MDS Sessions: treating MDS around the world
Advances in the amyloidosis space: Prognostic factors, CAEL-101 immunotherapy and real-world data
Developments in CLL: MRD, LOXO-305 and venetoclax at ASH 2020
Myeloma at ASH 2020: talquetemab, CARTITUDE-1 & highlights
Advances in CAR T-cell therapies for lymphoma from ASH 2020
Moving forward in MPN: timing driver mutations and novel therapies from ASH 2020
The MDS sessions: lower-risk disease
The AML Sessions: FLT3-mutated disease
The Lymphoma Sessions: highlights from iwNHL 2020
The MDS sessions: clinical trial participation, endpoints & approvals
The AML sessions: venetoclax-based regimens
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Good Nurse Bad Nurse
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
The Peter Attia Drive
The Doctor’s Farmacy with Mark Hyman, M.D.